Triage for Early Recognition of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Prospective Diagnostic Accuracy Study
Background: Immune checkpoint inhibitors (ICIs) have transformed treatment across multiple solid tumors, but immune-related adverse events (irAEs) occur in approximately 40% of treated patients across all grades and require prompt recognition to limit morbidity. In settings with a high patient-to-oncologist ratio, nu...